This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Blauth, C. Articles by Taylor, K. Search for Related Content PubMed Articles by Blauth, C. Articles by Taylor, K. Social Bookmarking                         What's this?

A double blind clinical trial of Iloprost during cardiopulmonary bypass

Cardiac Surgical Unit and Departments of Surgery and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

A. Brady

Cardiac Surgical Unit and Departments of Surgery and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

J. Arnold

Cardiac Surgical Unit and Departments of Surgery and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

J. Brannan

Cardiac Surgical Unit and Departments of Surgery and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

WE Schulenburg

Cardiac Surgical Unit and Departments of Surgery and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

R. Frackowiak

Cardiac Surgical Unit and Departments of Surgery and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

KM Taylor

Cardiac Surgical Unit and Departments of Surgery and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

Twenty patients undergoing elective coronary surgery were randomized to receive either the prostacyclin analogue Iloprost (Zk 36374) 5 ng/kg/min for 30 minutes before cardiopulmonary bypass (CPB) increasing to 10 ng/kg/min during CPB, or placebo, to investigate any beneficial effect on platelet preservation, or protection of the central nervous system during clinical CPB. Originally 50 patients were to have entered the trial, but unacceptable hypotensive effects occu rred in five patients who received Iloprost, lead i ng to early data analysis. No significant improvement in platelet number, volume or function; bleeding time; arterial line filter dry weight; retinal microembolism; or neuropsychological function, attributable to Iloprost, could be identified. The role and optimal dose of Iloprost in clinical CPB remains to be established.

Perfusion, Vol. 2, No. 4, 271-276 (1987)
DOI: 10.1177/026765918700200405


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. I. Blauth Macroemboli and Microemboli During Cardiopulmonary Bypass Ann. Thorac. Surg., May 1, 1995; 59(5): 1300 - 1303. [Abstract] [Full Text]

				D. Royston Interventions to reduce cerebral injury during cardiac surgery - the effect of physical and pharmacological agents Perfusion, April 1, 1989; 4(2): 153 - 161. [PDF]

				T. Spyt, D. Wheatley, I. Walker, J. Davidson, K. MacArthur, and W. Martin Placebo-controlled study of Iloprost (ZK 36374) in cardiopulmonary bypass surgery Perfusion, July 1, 1988; 3(3): 179 - 186. [Abstract] [PDF]